Overview

Biodistribution and Dosimetry of 99mTc-Duramycin

Status:
Completed
Trial end date:
2021-12-14
Target enrollment:
Participant gender:
Summary
Conduct a first-in-human study in healthy volunteers to show safety, biodistribution and dosimetry of [99mTc]Duramycin.
Phase:
Phase 1
Details
Lead Sponsor:
University Hospital, Antwerp
Collaborator:
Molecular Targeting Technologies, Inc.